Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition and diagnostics company that develops clinically supported nutrition, medical foods, supplements and medical devices, announced its financial results for the three months and nine months ended September 30, 2021. The Company also provided a corporate update to shareholders.

Financial highlights for the three months ended September 30, 2021 include the following:

  • Total revenue of $3,148,612 for the three months ended September 30, 2021, as compared to $253,188 for the three months ended September 30, 2020, reflecting the first full quarter of operations of the Viactiv brand, which represented approximately 95% of total revenue for the period. The Viactiv line of supplements was acquired by the Company on June 1, 2021.  
  • Net loss for the three months ended September 30, 2021 of $(3,014,836) or $(0.12) per share, as compared to a net loss of $(2,143,494) or $(0.15) per share for the three months ended September 30, 2020.
  • Cash and short-term investments balance of $10,558,662 and working capital of $12,896,498 at September 30, 2021.

Additional important events that occurred during the three months ended September 30, 2021 and subsequently include the following:

  • Completed the successful integration of the operations of the Viactiv brand and related systems into the Company’s operations.
  • Relocated the corporate offices from San Diego, California to Houston, Texas.
  • Entered into an agreement to terminate the lease on the Company’s San Diego, California corporate office and main warehouse facility, which was utilized primarily for the Company’s ocular products business. The termination agreement was effective on October 31, 2021 and is expected to reduce overhead costs. Guardion moved its product inventory to an experienced third-party logistics provider.
  • Launched a new and improved corporate and investor website to better engage with the Company’s investors, customers and other stakeholders. The website can be accessed at its current URL, www.guardionhealth.com.

Bret Scholtes, Guardion’s President and Chief Executive Officer, commented, “We are encouraged by our third quarter results, which demonstrated measurable progress towards our goal of building a leading clinical nutrition company. Our revenue growth, driven by the performance of the recently acquired Viactiv product line, represents the highest quarterly sales results in Guardion’s history. We achieved these results despite the challenging supply chain environment, and our management team is actively focusing on supply chain matters given industry-wide constraints. In addition, the Viactiv brand has been completely and successfully integrated into our business, and we remain confident in our ability to drive organic growth through expansion of the Viactiv brand. Our focus is now shifting to ways that we can successfully leverage the established distribution channels and brand awareness of Viactiv to accelerate the growth of the Company into a leader in clinical nutrition.

“Our efforts in the upcoming quarter will be concentrated on growing the market share of our current products, while at the same time expanding upon those attributes that we believe are fundamental to that growth. These include expanding Viactiv’s brand awareness and consumer acceptance through increased marketing and development of direct-to-consumer opportunities; leveraging and expanding our experienced management team; significantly growing our distribution networks and relationships while creating opportunities to develop new approaches and maximizing our product development and launch initiatives. We believe that this leveraging of the established Viactiv brand will be critical to establishing a consistent track record of growth in both revenue and profitability.”

Mr. Scholtes continued, “Over the long-term, Guardion believes that its success will depend on its ability to create value in well-differentiated and robust brands through strong clinically proven claims that address consumer needs in growing markets, both domestically and internationally. Guardion is committed to bringing compelling products to market that serve a distinct need, under meaningful and differentiated brands that are supported by strong science. We firmly believe that Guardion is now much better positioned to create value for its shareholders as a result of the Viactiv acquisition.”

“Mr. Scholtes concluded, “Finally, as we embark on this important work, we anticipate more opportunities to increase the frequency of shareholder communications to be able to report on achieving measurable and tangible milestones as part of the Company’s overall long-term progress.”

Financial Results Three Months Ended September 30, 2021 and 2020

Total revenue for the three months ended September 30, 2021 increased to $3,148,612, as compared total revenue for the three months ended September 30, 2020 of $253,188. The significant increase in revenue is due to the Company’s commercialization of its Viactiv products. We achieved these results despite the challenging supply chain environment. Management is actively focusing on supply chain matters in light of industry-wide supply chain constraints.  Through September 30, 2021, the Company has not experienced negative impacts to its supply chain, however, the Company cannot make any assurances in future periods.

Operating expenses for the three months ended September 30, 2021 were $4,403,545, as compared to operating expenses for the three months ended September 30, 2020 of $ 2,290,745.

Net loss for the three months ended September 30, 2021 was $(3,014,836), as compared to net loss for the three months ended September 30, 2020 of $(2,143,494).

These results of operations are not comparable to prior periods as we have significantly increased our gross revenues and cost of goods sold with our acquisition and successful integration of Activ.

Nine Months Ended September 30, 2021 and 2020

Total revenue for the nine months ended September 30, 2021 was $4,605,628, as compared total revenue for the nine months ended September 30, 2020 of $1,689,820. The change in overall performance in 2021 as compared to 2020 is attributable to the Company’s acquisition and successful integration of the Viactiv brand and product line on June 1, 2021.

Operating expenses for the nine months ended September 30, 2021 were $12,272,371, as compared to operating expenses for the nine months ended September 30, 2020 of $6,018,137.

Net loss for the nine months ended September 30, 2021 was $(10,224,649) as compared to net loss for the nine months ended September 30, 2020 of $(5,197,567).

These results of operations are not comparable to prior periods as we have significantly increased our gross revenues and cost of goods sold with our acquisition and successful integration of Activ.

About Guardion Health Sciences, Inc.

Guardion Health Sciences, Inc. (Nasdaq: GHSI), is a clinical nutrition and diagnostics company. Guardion’s portfolio of science-based, clinically supported nutrition, medical foods, and diagnostic products support healthcare professionals, their patients, and consumers in achieving health goals. Guardion’s commercial and developmental initiatives are supported by equally impressive scientific and medical advisory boards, led by seasoned business executives and physicians with many years of experience. This combination of expertise and scientific knowledge forms the foundation of Guardion’s growing position within the clinical nutrition marketplace. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the U. S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.

Forward-Looking Statement Disclaimer

With the exception of the historical information contained in this news release, the matters described herein may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions regarding our product development and commercialization efforts, research and development efforts, business, financial condition, results of operations, strategies or prospects, and other similar matters. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” “hopes” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, and involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the integration of new management team members, the implementation of new financial, management, accounting and business software systems, the integration of the Viactiv acquisition and possibly additional acquisition targets, the impact of the COVID-19 pandemic on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s listing requirements. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:CORE IRScott Arnold516-222-2560scotta@coreir.com

Media Relations Contact:Jules AbrahamDirector of Public RelationsCORE IR917-885-7378julesa@coreir.com

 
Guardion Health Sciences, Inc.Condensed Consolidated Balance Sheets
 
    September 30,     December 31,  
    2021     2020  
      (Unaudited)          
Assets                
                 
Current assets                
Cash   $ 3,563,854     $ 8,518,732  
Short-term investments     6,994,808       -  
Accounts receivable, net     2,268,623       11,248  
Inventories     792,633       384,972  
Prepaid expenses     1,246,711       179,931  
                 
Total current assets     14,866,629       9,094,883  
                 
Property and equipment, net     269,487       285,676  
Intangible assets, net     11,553,333       50,000  
Goodwill     11,893,134       -  
Deposits     1,282       11,751  
Right of use asset, net     29,305       418,590  
                 
Total assets   $ 38,613,170     $ 9,860,900  
                 
Liabilities and Stockholders’ Equity                
                 
Current liabilities                
Accounts payable   $ 1,182,955     $ 608,313  
Accrued expenses     473,257       127,637  
Operating lease liability – current     313,909       162,845  
Payable to former officer     -       148,958  
Derivative warrant liability     -       25,978  
                 
Total current liabilities     1,970,121       1,073,731  
                 
Operating lease liability – long term     -       271,903  
                 
Total liabilities     1,970,121       1,345,634  
                 
Commitments and contingencies                
                 
Stockholders’ Equity                
                 
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding     -       -  
Common stock, $0.001 par value; 250,000,000 shares authorized; 24,426,993 shares and 15,170,628 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively     24,427       15,171  
Additional paid-in capital     100,900,334       62,583,423  
Accumulated deficit     (64,281,712 )     (54,083,328 )
                 
Total stockholders’ equity     36,643,049       8,515,266  
                 
Total liabilities and stockholders’ equity   $ 38,613,170     $ 9,860,900  
                 

 
Guardion Health Sciences, Inc.Condensed Consolidated Statements of Operations (Unaudited)
 
                         
    Three Months EndedSeptember 30,     Nine Months EndedSeptember 30,  
    2021     2020     2021     2020  
                         
Revenue                                
Clinical nutrition   $ 3,109,525     $ 142,556     $ 4,443,113     $ 1,446,584  
Diagnostics equipment     39,087       110,632       162,515       237,136  
Other     -       -       -       6,100  
Total revenue     3,148,612       253,188       4,605,628       1,689,820  
                                 
Cost of goods sold                                
Clinical nutrition     1,730,318       68,956       2,454,423       764,245  
Diagnostics equipment     30,268       45,157       104,417       101,077  
Other     -       -       -       2,478  
Total cost of goods sold     1,760,586       114,113       2,558,840       867,800  
                                 
Gross profit     1,388,026       139,075       2,046,788       822,020  
                                 
Operating expenses                                
Research and development     16,234       34,034       53,598       109,803  
Sales and marketing     777,526       167,213       1,754,321       1,175,126  
General and administrative     3,297,725       2,070,998       8,048,713       5,299,696  
Transaction costs related to acquisition of Activ Nutritional, LLC     -       -       2,103,680       -  
Impairment of right of use asset and lease deposit     280,176       -       280,176       -  
Impairment loss on equipment held for sale     -       -       -       30,948  
Loss on disposal of fixed assets     31,883       18,500       31,883       18,500  
Costs related to resignation of former officer (including the reversal of previously recognized stock compensation expense of $965,295 during the nine months ended September 30, 2020)     -       -       -       (615,936 )
                                 
Total operating expenses     4,403,545       2,290,745       12,272,371       6,018,137  
                                 
Loss from operations     (3,015,518 )     (2,151,670 )     (10,225,583 )     (5,196,117 )
                                 
Other income (expense):                                
Interest expense     -       (3,716)       (14 )     (7,254 )
Interest income     682       -       948       -  
Change in fair value of derivative liability     -       11,892               5,804  
                                 
Total other income (expense)     682       8,176       934       (1,450 )
                                 
Net loss   $ (3,014,836 )   $ (2,143,494 )   $ (10,224,649 )   $ (5,197,567 )
                                 
Net loss per common share – basic and diluted   $ (0.12 )   $ (0.15 )   $ (0.44 )   $ (0.37 )
Weighted average common shares outstanding – basic and diluted     24,426,993       14,720,087       23,413,055       14,088,395  
                                 
    For the Three Months Ended September 30, 2021  
    Corporate     Clinical Nutrition     Diagnostics Equipment     Total  
                         
Revenue   $ -     $ 3,109,525     $ 39,087     $ 3,148,612  
                                 
Cost of goods sold     -       1,730,318       30,268       1,760,586  
                                 
Gross profit             1,379,207       8,819       1,388,026  
                                 
Stock compensation expense     364,448       -       -       364,448  
                                 
Operating expenses     1,166,837       2,802,886       69,373       4,039,097  
                                 
Loss from operations   $ (1,531,285 )   $ (1,423,679 )   $ (60,554 )   $ (3,015,518 )
                                 
                         
    For the Three Months Ended September 30, 2020  
    Corporate     Clinical Nutrition     Diagnostics Equipment     Total  
                         
Revenue   $ -     $ 142,556     $ 110,632     $ 253,188  
                                 
Cost of goods sold     -       68,956       45,157       114,113  
                                 
Gross profit     -       73,600       65,475       139,075  
                                 
Stock compensation expense             -       -       -  
                                 
Operating expenses     1,202,402       1,081,897       6,446       2,290,745  
                                 
Loss from operations   $ (1,202,402 )   $ (1,008,296 )   $ 59,028     $ (2,151,670 )
                                 
                         
    For the Nine Months Ended September 30, 2021  
    Corporate     Clinical Nutrition     Diagnostics Equipment     Total  
                         
Revenue   $ -     $ 4,443,112     $ 162,516     $ 4,605,628  
                                 
Cost of goods sold     -       2,454,402       104,418       2,558,819  
                                 
Gross profit     -       1,988,711       58,098       2,046,809  
                                 
Stock compensation expense     1,095,155       -       -       1,095,155  
                                 
Operating expenses     5,076,756       5,917,798       182,683       11,177,237  
                                 
Loss from operations   $ (6,171,911 )   $ (3,929,088 )   $ (124,585 )   $ (10,225,583 )
                                 
                         
    For the Nine Months Ended September 30, 2020  
    Corporate     Clinical Nutrition     Diagnostics Equipment     Total  
                         
Revenue   $ 6,100     $ 1,446,584     $ 237,136     $ 1,689,820  
                                 
Cost of goods sold     2,477       764,246       101,077       867,800  
                                 
Gross profit     3,623       682,338       136,059       822,020  
                                 
Stock compensation expense             -       -          
                                 
Operating expenses     2,655,107       3,146,514       216,516       6,018,137  
                                 
Loss from operations   $ (2,651,484 )   $ (2,464,176 )   $ (80,457 )   $ (5,196,117 )
                                 
Guardion Health Sciences (NASDAQ:GHSI)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024 Click aqui para mais gráficos Guardion Health Sciences.
Guardion Health Sciences (NASDAQ:GHSI)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024 Click aqui para mais gráficos Guardion Health Sciences.